PLYMOUTH - ProNAi Therapeutics Inc. Monday announced it has closed a Series C preferred financing round of more than $12 million with existing and new investors, the first of several planned financing activities for 2014. The company, in a press release, said the financing reflects ?the impressive clinical progress of the company over the past
ANN ARBOR - Learn how to access government funding for your bioscience company, especially from the Department of Defense during the MichBio sponsored webinar Jan. 17. The speaker, Liz Powell, is a former Legislative Director on Capitol Hill who staffed the Armed Services Committee and became an entrepreneur offering strategic counsel on how to navigate
LANSING - The federal Centers for Medicare and Medicaid Services late Monday gave its approval of Michigan's Medicaid eligibility expansion plan, meaning the state can move ahead with steps to enroll low-income individuals into the health care program. "It's a nice year-end gift for the governor and Legislature," Community Health Director James Haveman said in
GRAND RAPIDS - From artificial knees, to robotic surgery, to personalized DNA-based medicine. These technologies are improving patients' quality of life, enabling medical interventions and possibilities not imagined even 10 years ago. What's driving these changes, and is there a downside to all of this? Lean Jan. 8 when the MIT Enterprise Forum hosts Medical
ANN ARBOR ? MichBio is hosting a webinar Jan. 17 to look at what government funding may be available for the life sciences industry. Accessing Government Funding in a Changing Landscape will show viewers how to access government funding for your bioscience company, especially from the Department of Defense. Speaker, Liz Powell, is a former
LANSING - Neogen Corp. for the second quarter of its fiscal year, which ended Nov. 30, reported lower net income despite higher sales due to what a top executive called a year of ?clean crops.? Acquisition expenses also played a part. Sales for Neogen in the quarter were $59.6 million, up 15 percent from $50.7
PLYMOUTH - After nearly a decade in the city of Detroit, Genesis Genetics has moved its corporate headquarters to Plymouth. Tony Gordon Ph.D., Genesis Genetics Managing Director, leads the team of scientists, genetic counselors and case coordinators. In the United States, Genesis Genetics focuses its science on two important fertility technologies: Preimplantation Genetic Screening and
ANN ARBOR - Rubicon Genomics reported major gains in 2013 sales of its nucleic acid library preparation products, ThruPLEX-FD Prep Kits and PicoPLEX WGA Kits, resulting in an increase in company revenues of 85 percent. But the bioscience company did not report earnings. ?This has been a breakout year for Rubicon, as our expanded marketing
ANN ARBOR - Rubicon Genomics announced it has partnered with additional distributors globally to expand availability of its products that test DNA. Three new distribution partnerships have been signed for Europe. They include Amplitech for France, HPST for the Czech Republic and LuBio Science for Switzerland. Rubicon also completed new distribution agreements in Asia and
ROCHESTER HILLS - Oxford Biomedical Research has been awarded a $1,163,600 Phase 2 Small Business Innovation Research Grant by the National Institute of Environmental Health Sciences that will help Oxford develop tests designed to detect toxicity and differentiate potential toxic effects to multiple organs. GST proteins are found in many tissues and organs. They play